Search

Your search keyword '"Fu, Hai-Xia"' showing total 9 results
Start Over Author "Fu, Hai-Xia" Journal bone marrow transplantation
9 results on '"Fu, Hai-Xia"'

1. Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience

Author

Ma, Rui, primary, Zhu, Dan-Ping, additional, Zhang, Xiao-Hui, additional, Xu, Lan-Ping, additional, Wang, Yu, additional, Mo, Xiao-Dong, additional, Lv, Meng, additional, Zhang, Yuan-Yuan, additional, Cheng, Yi-Fei, additional, Yan, Chen-Hua, additional, Chen, Yu-Hong, additional, Chen, Yao, additional, Wang, Jing-Zhi, additional, Wang, Feng-Rong, additional, Han, Ting-Ting, additional, Kong, Jun, additional, Wang, Zhi-Dong, additional, Han, Wei, additional, Chen, Huan, additional, Chang, Ying-Jun, additional, He, Yun, additional, Xu, Zheng-Li, additional, Zheng, Feng-Mei, additional, Fu, Hai-Xia, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Sun, Yu-Qian, additional

Published
2024
Full Text
View/download PDF

2. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Author

Huang, Qiu-Sha, primary, Han, Tian-Xiao, additional, Chen, Qi, additional, Wu, Jin, additional, Zhao, Peng, additional, Wu, Ye-Jun, additional, He, Yun, additional, Zhu, Xiao-Lu, additional, Fu, Hai-Xia, additional, Wang, Feng-Rong, additional, Zhang, Yuan-Yuan, additional, Mo, Xiao-Dong, additional, Han, Wei, additional, Yan, Chen-Hua, additional, Wang, Jing-Zhi, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Ting-Ting, additional, Lv, Meng, additional, Chen, Yao, additional, Wang, Yu, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Zhang, Xiao-Hui, additional

Published
2023
Full Text
View/download PDF

3. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation

Author

Kong, Jun, primary, Zheng, Feng-Mei, additional, Wang, Zhi-Dong, additional, Zhang, Yuan-Yuan, additional, Cheng, Yi-Fei, additional, Fu, Hai-Xia, additional, Lv, Meng, additional, Chen, Huan, additional, Xu, Lan-Ping, additional, Zhang, Xiao-Hui, additional, Huang, Xiao-Jun, additional, and Wang, Yu, additional

Published
2023
Full Text
View/download PDF

4. Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study

Author

Yang, Li-Ping, primary, Zhao, Peng, additional, Wu, Ye-Jun, additional, Fu, Hai-Xia, additional, He, Yun, additional, Mo, Xiao-Dong, additional, Lv, Meng, additional, Wang, Feng-Rong, additional, Yan, Chen-Hua, additional, Chen, Yu-Hong, additional, Chang, Ying-Jun, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Zhang, Xiao-Hui, additional

Published
2022
Full Text
View/download PDF

5. Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation

Author

Wu, Jin, primary, Fu, Hai-Xia, additional, He, Yun, additional, Mo, Xiao-Dong, additional, Liu, Xiao, additional, Cai, Xuan, additional, Gui, Ruo-Yun, additional, Liu, Hui-Xin, additional, Yan, Chen-Hua, additional, Chen, Yu-Hong, additional, Chang, Ying-Jun, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Zhang, Xiao-Hui, additional

Published
2021
Full Text
View/download PDF

6. Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation

Author

Cai, Xuan, primary, Fu, Hai-Xia, additional, Mo, Xiao-Dong, additional, Wang, Yu, additional, Zhang, Yuan-Yuan, additional, Wu, Jin, additional, Han, Wei, additional, Tang, Fei-Fei, additional, Gui, Ruo-Yun, additional, Chen, Huan, additional, Chen, Yao, additional, Zhao, Peng, additional, Yan, Chen-Hua, additional, Wang, Jing-Zhi, additional, Chen, Yu-Hong, additional, Chang, Ying-Jun, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Zhang, Xiao-Hui, additional

Published
2020
Full Text
View/download PDF

7. Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation

Author

Yan, Chen-Hua, primary, Wang, Yu, additional, Mo, Xiao-dong, additional, Sun, Yu-Qian, additional, Wang, Feng-rong, additional, Fu, Hai-xia, additional, Chen, Yao, additional, Han, Ting-ting, additional, Kong, Jun, additional, Cheng, Yi-fei, additional, Zhang, Xiao-hui, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2020
Full Text
View/download PDF

8. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes

Author

Chen, Qi, Zhao, Xin, Fu, Hai-Xia, Chen, Yu-Hong, Zhang, Yuan-Yuan, Wang, Jing-Zhi, Wang, Yu, Wang, Feng-Rong, Mo, Xiao-Dong, Han, Wei, Chen, Huan, Chang, Ying-Jun, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a gradually recognised neurological complication of allogenic haematopoietic stem cell transplantation (allo-HSCT). However, there is a paucity of information on PRES after haploidentical HSCT (haplo-HSCT). We performed a retrospective nested case-control study in patients following haplo-HSCT for malignant and nonmalignant haematologic diseases between January 2009 and December 2018 in our centre. A total of 45 patients were diagnosed with PRES after transplant, accounting for an incidence of 1.17%. Grades II to IV acute graft-versus-host disease (aGVHD) (HR 2.370, 95% CI 1.277–4.397, p= 0.006) and hypertension (HR 14.466, 95% CI 7.107–29.443, p< 0.001) were identified as risk factors for developing PRES after haplo-HSCT. There was no difference in overall survival (OS), disease-free survival (DFS), the cumulative incidence of relapse or nonrelapse mortality (NRM) between patients with PRES and controls without PRES following haplo-HSCT in either adults or children. All but one patient with PRES showed nearly complete clinical and neurologic recovery. In conclusion, PRES is a rare condition with benign outcomes following haplo-HSCT. Further multicentre prospective studies are needed to confirm the results and help to establish the standard therapy for posttransplant PRES.

Published
2020
Full Text
View/download PDF

9. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Author

Huang QS, Han TX, Chen Q, Wu J, Zhao P, Wu YJ, He Y, Zhu XL, Fu HX, Wang FR, Zhang YY, Mo XD, Han W, Yan CH, Wang JZ, Chen H, Chen YH, Han TT, Lv M, Chen Y, Wang Y, Xu LP, Liu KY, Huang XJ, and Zhang XH

Subjects
Humans, Prognosis, Retrospective Studies, Risk Factors, Bronchiolitis Obliterans therapy, Bronchiolitis Obliterans Syndrome, Hematopoietic Stem Cell Transplantation adverse effects
Abstract

Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating noninfectious pulmonary complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, predictive tools for BOS are not available. We aimed to identify the clinical risk factors and establish a prognostic model for BOS in patients who undergo allo-HSCT. We retrospectively identified a cohort comprising 195 BOS patients from 6100 consecutive patients who were allografted between 2008 and 2022. The entire cohort was divided into a derivation cohort and a validation cohort based on the time of transplantation. Via multivariable Cox regression methods, declining forced expiratory volume at 1 s (FEV1) to <40%, pneumonia, cGVHD except lung, and respiratory failure were found to be independent risk factors for the 3-year mortality of BOS. A risk score called FACT was constructed based on the regression coefficients. The FACT model had an AUC of 0.863 (95% CI: 0.797-0.928) in internal validation and 0.749 (95% CI: 0.621-0.876) in external validation. The calibration curves showed good agreement between the FACT-predicted probabilities and actual observations. The FACT risk score will help to identify patients at high risk and facilitate future research on developing novel, effective interventions to personalize treatment., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results